Orbactiv sales history revenue
WebORBACTIV® (oritavancin) for injection J code is J2407 injection, oritavancin, 10 mg. Reimbursement Guide Executive Summary Sample Billing Forms Revised Q1 2024 … WebFacilitating access to Orbactiv® (oritavancin) for your patients. 1-844-ORBACTIV (1-844-672-2284) Monday - Friday, 8:00 AM - 8:00 PM ET or email us. Medical Information. For medical inquiries or to report an adverse event, other safety related information, or product complaints for a company product, please contact Medical Information. ...
Orbactiv sales history revenue
Did you know?
WebOrbactiv (oritavancin) is a newer antibiotic that treats skin infections caused by certain bacteria. It's commonly used for people who have, or might have, an infection from resistant bacteria. It's given as an injection through the veins for one dose and is available as a brand-name medication only, which can be expensive. COMMON BRANDS WebORBACTIV® is contraindicated in patients with known hypersensitivity to oritavancin products. Warnings and Precautions Coagulation test interference: Oritavancin has been …
WebFeb 22, 2024 · Orbactiv (oritavancin) for injection is an antibiotic used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram -positive microorganisms: Staphylococcus aureus (including methicillin -susceptible and methicillin-resistant isolates), Streptococcus pyogenes, …
WebORBACTIV® is available at your major wholesalers and through direct purchase. Please use standard ordering procedure through your wholesaler by calling your wholesaler’s customer service number listed below: AmerisourceBergen Customer CARE: (844) 222-2273. Anda Customer Service: (800) 331-2632. Besse Medical Customer CARE: (800) 543-2111. WebJun 23, 2016 · The company launched Orbactiv in the US market in October 2014. Other medications available in the market to treat ABSSSI include Dalvance (dalbavancin) developed by Durata Therapeutics and Sivextro developed by Cubist Pharmaceuticals.
WebSales history aids analysts in determining current sales trends and identifying patterns of buying behaviour or revenue cycles. One or more of the following can be used to identify these trends: 1. The kind of product 2. Sales territory 3. The time of year 4. Customer groups (by gender, age, occupation, and so on)
Web*INDICATION AND USAGE. Both KIMYRSA ® and ORBACTIV ® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin … how many calories burned in 45 minute walkWebHeadquarters United States Website www.orbactiv.com Revenue <$5M Is this data correct? Popular Searches Orbactiv SIC Code 28,283 NAICS Code 32,325 Show More Top … how many calories burned in 4 mile bike rideWebOrbactiv (oritavancin) is an antibiotic. It fights against certain bacteria called Gram-positive bacteria. The medication works by preventing the bacteria from making their protective … high quality printing dubaiWebSales Leadership & Product Market Growth - Increased Orbactiv utilization by 270 units in 2016 verses 2015 for an increase of $783k and total Orbactiv sales revenue of $2.1 million;... high quality printer for photosWebInfusion Related Reactions: Administer ORBACTIV® over 3 hours to minimize infusion-related reactions. Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products (e.g. ORBACTIV®), including after the administration of more than one dose of oritavancin during a single course high quality printer paperWebExperienced sales leader with a demonstrated history in the hospitality industry providing exceptional customer service. Skilled in Destination Management, Food & Beverage, Hotel … high quality printer floridaWebORBACTIV infusion in patients with a history of glycopeptide allergy. In the Phase 3 ABSSSI clinical trials, the median onset of hypersensitivity reactions in ORBACTIV-treated patients was 1.2 days and the median duration of these reactions was 2.4 days. [see Adverse Reactions (6.1)] 5.4 . Infusion Related Reactions high quality printing folding machine